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Introduction
Metastable thermodynamic states are frequently en-
countered in pharmaceutical systems, in the intentional
or unintentional creation of supersaturation, in the crystal-
lization of desired solid-state modifications, and in the
control of solid-phase conversions during isolation, manu-
facturing, storage, and dissolution.1-4 Some examples in
which metastable states are encountered include solid
solutions, freeze-concentrated solutions, solutions of weak
acids or bases exposed to a pH change, solutions prepared
by dissolving a solid-state modification with a higher
solubility (higher free energy), and residual solutions
during filtration, granulation, and drying. Because crystal-
lization provides a way of reducing the free energy of
metastable thermodynamic states, the extent to which
metastable states can be maintained is determined by the
crystallization mechanisms and kinetics.5-16 What is sur-
prising, however, is that despite the important role that
crystallization has in process control and in determining
solid-phase outcomes, crystallization phenomena are often
neglected in the pharmaceutical industry until a problem
is encountered.
While emphasis is often given to the knowledge of
equilibrium phase diagrams with the purpose of identifying
the concentration and temperature regions of thermody-
namic stability of solid phases, information on crystalliza-
tion processes can only be obtained by combining studies
of thermodynamic properties with kinetic measurements.
Cases of unwanted or previously unknown nucleation
events abound. Dunitz and Bernstein17 documented cases
of “disappearing or elusive polymorphs” that provide
evidence for the consequences of poor process control in
crystallization of polymorphic systems. The recent shortage
in the supply of capsules of the HIV protease inhibitor
Norvir (indinavir), due to the sudden formation of a
crystalline structure different from the one harvested for
months,18 illustrates the decisive role that nucleation
mechanisms and kinetics have on crystallization. Nichols
and Frampton19 have reported considerable efforts that
failed to crystallize the metastable polymorph of paraceta-
mol as described in the initial publication of the crystal
structure.20 The critical role of crystallization kinetics in
determining the appearance of crystalline modifications is
also recognized by the FDA and described in the guidelines
for the manufacture of drug substances:21 “Appropriate
manufacturing and control procedures (including in-process
testing when needed) should be established for the produc-
tion of the desired solid-state form(s). It should be empha-
sized that the manufacturing process (or storage condition)
is responsible for producing particular polymorphs or
solvates; the control methods merely determine the out-
come.”
Even when the parameters that regulate crystallization
phenomena are neglected, the illusion of process control is
motivated by a crystallization process that yields the
desired productssolid phase modification, shape, or size
distributionsand by the robust analytical methods used
for solid state characterization. This situation is greatly
complicated by the recent emphasis on an exclusively
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structural approach due to the availability of commercial
software for the prediction of crystal structure from mo-
lecular structure (ab initio predictions) while kinetic pro-
cesses are scarcely investigated. Desiraju22-24 and Gave-
zzotti25-29 have discussed the various methods for crystal
structure and polymorphism prediction and the capabilities
and shortcomings of the various computer simulation
techniques. The main challenge lies in determining the
relationships between the molecular aggregation pathways
that cause some nuclei to grow and the structure and
thermodynamics of the crystalline solids. Recent work from
various groups14,30-40 highlight the importance of combining
computer simulations with experimental methods to in-
vestigate the molecular events that lead to crystallization.
The purpose of this review is to describe ways in which
crystal structure, morphology, and crystallization kinetics
can be utilized to reproducibly maintain metastable states
and control solid-state outcomes. Experimental methods
that can be employed to investigate the factors that
regulate crystallization from solution will be presented.
Crystallization
A crystalline phase is created as a consequence of
molecular aggregation processes in solution that lead to
the formation of nuclei (with a configuration compatible
with the crystal structure), which achieve a certain size
for a sufficient time to enable growth into macroscopic
crystals. The rate and mechanisms by which crystals are
formed in liquid solutions is determined by the solubility,
supersaturation, rate at which supersaturation is created,
diffusivity, temperature, and the reactivity of surfaces
toward nucleation.41-45
Transferability of crystallization microtechniques to
larger scale processes that are reproducible requires iden-
tification of crystallization mechanisms and kinetics. While
operationally useful variables that describe crystallization
methods are often related to crystallization outcomes, this
approach lacks meaningful information for developing a
process that yields reliable outcomes, since the factors that
determine the crystallization kinetics and outcomes are not
explicitly considered. For instance, compare the following
two approaches to describe the processes for the selective
crystallization of polymorphs: (1) form I obtained by
cooling, form II obtained by evaporation, and (2) form I
obtained at a supersaturation x, temperature y, and time
z at which crystals were harvested after crystallization
onset; form II obtained at supersaturation x′, etc. While
the former approach is at best anecdotal, the latter employs
the causative factors and leads to relationships between
the crystallization kinetic parameters and the outcomes.
Control of the processes of nucleation and crystal growth
is possible as long as the required information is available.
Dunitz and Bernstein17 have explained the mystery of
disappearing polymorphs by considering various examples
and the relevant questions that were left unanswered. They
state that “once a particular polymorph has been obtained,
it is always possible to obtain it again; it is only a matter
of finding the right experimental conditions.”
Supersaturation
Knowledge of the driving force for crystallization is
essential, not only to characterize the kinetics, but also to
relate the crystallization outcomes to the parameters that
regulate crystallization. The number of molecules necessary
to achieve an effective nucleating cluster is inversely
proportional to the supersaturation. Therefore, as the
supersaturation is increased the probability of nucleation
increases. However, nucleation is energetically more de-
manding than crystal growth, and there are supersatura-
tion regions in which crystal growth proceeds while nucle-
ation is suppressed.41,42,44
The driving force for nucleation and growth is the
difference in chemical potential of the solute in a super-
saturated solution, µ1, and in a saturated solution, µeq:
Since µ ) µ° + RT ln a, then
and the supersaturation is
If the activity coefficient, γ, is independent of concentra-
tion, in the given concentration regime, then γ1 ) γeq and
the supersaturation becomes
where c is the concentration of the crystallizing substance
in the supersaturated solution and s is the solubility. (This
notation is adopted to avoid the use of subscripts.) A
frequently used definition for the supersaturation is
For c/s values smaller than 1.15,
Supersaturation may be created by various methods that
regulate the solute activity (concentration) or activity
product. These include (a) solvent removal (evaporation or
freezing), (b) addition of indifferent salts with ions that
participate in precipitation, and (c) dissolution of meta-
stable solid phases. Supersaturation can also be created
by methods that regulate the solute solubility, such as
temperature change, pH change, and addition of a solvent
that lowers the solubility of the solute.
Nucleation
Nucleation is often the decisive step in the crystallization
process and is of practical importance in pharmaceutical
systems. For instance, questions regarding the concentra-
tion threshold above which crystallization is observed at
times shorter than the desired product shelf life, or dilution
rates and concentrations above which precipitation occurs
upon injection, are related to the kinetic stability of
supersaturated solutions and are regulated by the nucle-
ation mechanisms and kinetics. Nucleation phenomena are
equally important in the control of micromeritic properties
and in the selective crystallization of a particular poly-
morph.
In general, nucleation mechanisms can be divided into
two main categories: homogeneous and surface or interface
catalyzed.42-44,46 Homogeneous nucleation rarely occurs in
large volumes (greater than 100 µl) since solutions contain
random impurities which may induce nucleation.47,48 This
type of nucleation is referred to as heterogeneous. A surface
or an interface of different composition than the crystal-
lizing solute may serve as a nucleation substrate, by
decreasing the energy barrier for the formation of nuclei
that can grow into mature crystals. Nucleation that is
promoted by crystals of the crystallizing solute is known
∆µ ) (µ1 - µeq) (1)
∆µ ) RT ln (a1/aeq) ) RT ln (γ1c1/γeqceq) (2)
σ ) ∆µ/RT ) ln (a1/aeq) ) ln (γ1c1/γeqceq) (3)
σ ) ln (c1/ceq) ) ln (c/s) (4)
σ ≡ (c - s)/s (5)
σ ) ln (c/s) ≈ (c - s)/s (6)
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as secondary nucleation. These mechanisms are thoroughly
discussed by Mullin,42 Myerson,44 and Zettlemoyer.46
Homogeneous NucleationsThermodynamic consid-
erations for nucleation are based on the work of Gibbs,49
Volmer 50 and others, where the free energy change for an
aggregate undergoing a phase transition ∆G is given by
where ∆Gs is the surface free energy change associated
with the formation of the aggregate (a positive quantity),
and ∆Gv is the volume free energy change associated with
the phase transition (a negative quantity). For homoge-
neous or heterogeneous nucleation
where R is the volume-shape factor, l is the characteristic
length, υ is the molecular volume of the crystallizing solute,
kB is Boltzmann’s constant, and T is temperature. For
homogeneous nucleation
where â is the area shape factor and γ is the interfacial
energy per unit area between the crystallization medium,
1, and the nucleating cluster, 2. Consequently, the overall
free energy change for nucleation is decreased by a large
supersaturation ratio (c/s) and by a low interfacial energy.
The factors that regulate nucleation are best appreciated
by considering the equation for the rate of homogeneous
nucleation from solutions:
J is the number of nuclei formed per unit time per unit
volume, No is the number of molecules of the crystallizing
phase in a unit volume, ν is the frequency of atomic or
molecular transport at the nucleus-liquid interface, and
∆G* is the maximum in the Gibbs free energy change for
the formation of clusters, at a certain critical size, l*. The
nucleation rate was initially derived for condensation in
vapors by Becker and Döring,51 where the preexponential
factor is related to the gas kinetic collision frequency. In
the case of nucleation from condensed phases, the fre-
quency factor is related to the diffusion process.52 The value
of l* can be obtained by minimizing the free energy function
with respect to the characteristic length
For spherical clusters, R ) 4π/3 and â ) 4π based on
the cluster radius. Therefore,
Considering these geometric factors, the rate for homo-
geneous nucleation of spherical clusters is
While the classical theory of nucleation is limited by the
implicit assumptions in its derivation (described in detail
in ref 41) it successfully predicts the nucleation behavior
of a system.42-44,46,53 Inspection of the equation above
clearly suggests that the nucleation rate can be experi-
mentally controlled by the following parameters: molecular
or ionic transport, viscosity, supersaturation, solubility,
solid-liquid interfacial tension, and temperature.
Nucleation kinetics are experimentally determined from
measurements of nucleation rates, induction times and
metastability zone widths (the supersaturation or under-
cooling necessary for spontaneous nucleation) as a function
of initial supersaturation.41-43,54 The nucleation rate will
increase by increasing the supersaturation while all other
variables are constant. However, at constant supersatu-
ration the nucleation rate will increase with increasing
solubility. Solubility affects the pre-exponential factor and
the probability of intermolecular collisions. Furthermore,
when changes in solvent or solution composition lead to
increases in solubility, the interfacial energy decreases
since the affinity between crystallizing medium and crystal
increases.41 Consequently, the supersaturation required for
spontaneous nucleation decreases with increasing solubil-
ity,55 as shown in Figure 1.
The dependence of nucleation rate on solubility is also
consistent with Ostwald’s law of stages56 regarding the
preferential formation of a metastable solid phase, that
states the following: “when leaving an unstable state, a
system does not seek out the most stable state, rather the
nearest metastable state which can be reached with loss
of free energy”. This indicates that if the unstable solid-
state modification (the system with highest solubility)
precipitates before more thermodinamically stable solid
phases, it must have higher nucleation and growth rates
than solid states of lower solubility. However, Ostwald’s
law of stages is not universally valid because the appear-
ance and evolution of solid phases are determined by the
kinetics of nucleation and growth under the specific
experimental conditions.5,6,13
Accounts of nucleation inhibition in the pharmaceutical
literature are sometimes confusing because the dependence
of the nucleation event (nucleation rate, metastability zone
width, or induction time) on supersaturation is not con-
sidered. In search for additives that inhibit nucleation,














J ) Noν exp( -16πυ2γ1233(kBT)3(ln(cs))2) (13)
Figure 1sDependence of the critical supersaturation for nucleation on solubility
of nitrofurantoin in (1) formic acid, (2) formic acid:water (4:1), (3) formic acid:
ethanol (2:1), (4) formic acid:dioxane (2:1), (5) formic acid:methanol (2:1), (6)
formic acid:water (2:1). Data from ref 55.
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induction times are often measured as a function of
additive concentration while the dependence of the nucle-
ation event on supersaturation is neglected. Results from
such studies possibly lead to the erroneous conclusion that
the additive inhibited nucleation57,58 when indeed the
additive decreased the supersaturation, and frequently led
to an undersaturated state. Hence, the system is under
thermodynamic control instead of kinetic control.
An important factor contributing to the nucleation
mechanism and kinetics is the volume of solution in which
nucleation occurs. The dispersal of a bulk liquid into a
collection of small droplets has been shown to be an
effective way of achieving large supersaturations or un-
dercoolings.47,48 Precipitation and solidification in small
volumes (droplets) involving emulsions have been used to
study homogeneous nucleation processes,59 and to control
purity, particle size, and morphology.60,61 Dispersing a
solution into small volumes isolates heterogeneous nucle-
ants within a fraction of the drops and makes nucleation
more difficult. Consequently, larger supersaturations need
to be reached for nucleation to occur. The boundaries of
possible outcomes are represented by the following sce-
narios: (1) crystals of very small size (even in the nanom-
eter range) are formed as a result of the high nucleation
rates,60,61 or (2) a glass or amorphous solid is formed due
to the low diffusion rates of molecules that inhibit the
evolution of clusters to crystals within the time scale of
the experiment.62
Nucleation outcomes from solutions with initially the
same composition may vary as a consequence of impurities,
rates at which supersaturation was created, thermal
histories, experimental techniques employed to detect
precipitation, and solution volumes in which nucleation
occurred. An important factor contributing to the changes
in pH during freezing of buffer solutions is the selective
crystallization of buffer components.63-66 The salt and
buffer concentrations for precipitation of disodium phos-
phate during freezing of sodium phosphate buffer solutions
among various laboratories are shown in Table 1. Murase
et al.63,64 report higher initial buffer and disodium phos-
phate concentrations for the precipitation of disodium
phosphate, compared to results from our laboratory.66 The
fraction of disodium phosphate precipitated was observed
to decrease with decreasing the initial buffer concentration
below 500 mM, at 200 mM disodium phosphate concentra-
tion, versus an initial buffer concentration below 8 mM,
at 0.3 mM disodium phosphate concentration in our stud-
ies;66 furthermore, disodium phosphate did not precipitate
at initial disodium salt concentrations below 10 mM63,64
while our studies show that precipitation occurs at salt
concentrations as low as 0.3 mM.66 Inspection of the
experimental conditions under which these studies were
done (Table 2) shows a trend toward slower salt precipita-
tion rates with decreasing volume of solutions from 25 mL
to 3 µl and increasing rates of cooling to lower tempera-
tures.
Neglecting the factors that regulate nucleation leads to
misleading generalizations when developing guidelines to
control precipitation by the addition of noncrystallizing
additives. Consider, for example, the conflicting interpreta-
tion of additive effects on nucleation when these are
expressed in terms of concentration ratios (additive to
crystallizing solute) while ignoring other parameters. Data
in Table 1 indicates that disodium phosphate precipitation
is inhibited at (H2PO4-/HPO42-) ) 4 (0.73 M/0.19 M)65
while it is not inhibited at (H2PO4-/HPO42-) ) 16 (0.094
M/0.006 M).66 Compared to the systems we studied,66 the
buffers studied by Cavatur and Suryanarayana65 have
much higher concentrations of monosodium phosphate
(which increase the viscosity of solutions), smaller solution
volumes, and faster rates of cooling to lower temperatures.
All these factors contribute to delaying salt precipitation.
The effect of the viscosity of the crystallization medium
on the nucleation rate has been described by Turnbull and
Fisher.52 The frequency of atomic or molecular transport
at the nucleus-liquid interface can be related to the bulk
viscosity, η, with the Stokes-Einstein relation:
where ao is the mean effective diameter of the diffusing
species. If the viscosity dependence on temperature is
described by Arrhenius behavior, then
where ∆Ga is the activation energy for transport across the
nucleus-liquid interface. Thus, the nucleation rate may
go through a maximum when an increase in undercooling
or supersaturation is accompanied by an increase in
viscosity. This behavior has been observed in the nucleation
of citric acid in aqueous solutions,67 and the crystallization
of ice.68
Heterogeneous NucleationsHeterogeneous nucle-
ation processes are of fundamental and practical impor-
tance in pharmaceutical systems since unintentionally or
intentionally added surfaces or interfaces may promote
nucleation. The reactivity of crystals surfaces as hetero-
geneous nucleants has significant consequences in the
isolation of the desired solid-state modification and in the
control of conversions between these modifications, since
the free energy required for the formation of two-dimen-
sional nuclei is lowered by the presence of an appropriate
substrate. Quantitatively this is described by the following
equation:69,70
Table 1sComparison of Crystallization Behavior of Disodium
Phosphate during Far-from-Equilibrium Freezing of Buffer Solutions




Murase and Franks63,64 crystallization begins to
decrease
e200





by CNaH2PO4b g 730 mM
190
Gómez66 crystallization begins to
decrease
e15
crystallization readily occurs g0.3
crystallization is not inhibited
at CNaH2PO4 e 94 mM
6
a CNa2HPO4 ) initial disodium phosphate concentration in solution at 25 °C.
b CNaH2PO4 ) initial monosodium phosphate concentration in solution at
25 °C.
Table 2sExperimental Conditions and Methods of Measuring
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where γ is the interaction energy per area, A is the surface
area of the interfaces, and the subscript 3 represents the
substrate. The total change in surface free energy will be
lowered by favorable surface interactions between the
aggregate and the substrate and unfavorable interactions
between the crystallization medium and the substrate, due
to the negative value of the second term in eq 16. Conse-
quently, nucleation will be enhanced by increasing the
surface area of the substrate.
The effectiveness of crystal seeding in controlling crys-
tallization outcomes relies on the potential of crystal
surfaces to promote heterogeneous or secondary nucle-
ation,42,43 while avoiding heterogeneous nucleation medi-
ated by unknown contaminants. A review by Ward71 on the
structure, properties, and reactivity of organic crystal
surfaces is recommended to develop strategies for the
choice of surfaces that promote nucleation. Various
studies8,72-75 have demonstrated the influence of substrate
topography, lattice parameters, crystallographic symmetry
and intermolecular interactions on surface-directed nucle-
ation.
Heterogeneous nucleation mechanisms can significantly
affect dissolution of metastable solid phases, because this
form of nucleation can occur at low driving forces. While
the choice of a metastable solid phase with a solubility
higher than other crystalline modifications is motivated by
the expectation of faster dissolution rates, achievement of
faster dissolution rates and higher concentrations in solu-
tions is jeopardized by surface-mediated nucleation events.
We have reported8 that the surface of the metastable phase
of theophylline promoted the nucleation of the stable
monohydrate crystals. The observed oriented growth of
monohydrate crystals on the anhydrous surface is consis-
tent with a close lattice match between the b and c
crystallographic axes.8 Other studies on the dissolution of
metastable solids such as anhydrous theophylline76 and
anhydrous carbamazepine77-79 have shown that crystal-
lization of the stable phase occurs during dissolution,
Figure 2. It is unfortunate that in view of the important
influence that nucleation mechanisms have on dissolution
of metastable solid phases, very seldom are studies carried
out to identify the potential of substrate-mediated nucle-
ation by the metastable modification. The information
gained from this type of study can be used in the design of
methods to regulate crystallization during dissolution as
well as during isolation of the desired solid form.
Carter and Ward70 have identified a surface-mediated
nucleation mechanism that involves a geometric shape
match between planes of a ledge site on the substrate and
planes of prenucleation aggregates. They have applied
these concepts to the directed nucleation of polymorphs.72,74
This work provides us with the attractive possibility that
“a library of organic seeds can be used to control polymor-
phism, or to search for unknown polymorphs”.71 Molecular
interpretations based on this approach are experimentally
more accessible than those based on solvent-selective
polymorph crystallization.
Experimental and Computational StrategiessWhile
nucleation phenomena have their origin at the molecular
level, they are often described in terms of macroscopic
properties due to the scarcity of experimental techniques
that allow for monitoring events at the molecular level.
Nevertheless, information about molecular association
processes in supersaturated systems obtained by laser
Raman spectroscopy and laser light scattering has been
used to identify prenucleation clusters and growth units
under well-defined experimental conditions. Methods that
measure cluster size distributions are more appropriate for
studying crystallization of macromolecules80-84 due to the
large sizes of prenucleation clusters, while Raman and
fluorescence spectroscopic techniques are capable of provid-
ing information about the solution structure or the species
present in solution.85-88 The implications for crystallization
pathways are examined by comparing the solution and
crystal structures at a molecular level, and by combining
information obtained from macroscopic analysis with re-
sults from molecular simulations.14,31-40
Desiraju22-24 and Gavezzotti26-29 have described crystal
engineering strategies to understand the molecular ag-
gregation processes involved in crystallization and to
elucidate the supramolecular motifs in organic crystals. In
this context, crystals are viewed as solid-state supermol-
ecules assembled by intermolecular interactions, with the
basic approach of establishing a relation between molecular
interactions and supramolecular structure. Recent studies
by Gavezzotti29 show how molecular dynamics calculations
allow for simulation of solvent and kinetic effects on
molecular aggregation.
The supramolecular assembly process can be controlled
so that the precursor nuclei in solution adopt a structure
that resembles the structure of the desired crystalline
modification.29,89,90 This concept has been used in the design
of nucleation inhibitors to prevent growth of the stable
polymorph and enhance the growth of the metastable
polymorph.13,15,16 Davey et al.14 have explained the solvent-
dependent polymorph appearance of sulfathiazole by ana-
lyzing the intermolecular interactions in the various poly-
morphic structures and comparing them with the supramole-
cular assemblies that could exist in the different solvents.
In this case, however, the solvent-dependent selective
crystallization of a polymorph was not correlated with
solubility.14,91
Strategies used for the rational choice of additives to
selectively inhibit nucleation or growth of the thermody-
∆Gs ) γ12A12 + (γ23 - γ13)A23 (16)
Figure 2sNucleation and growth of dihydrate carbamazepine on crystal faces
of anhydrous monoclinic carbamazepine in aqueous solutions of sodium lauryl
sulfate (17.3 mM, 0.5%), supersaturation ratio of 1.15 at 25 °C. From ref 79.
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namically stable modification are based on the work of
Davey,12-14,92 Leiserowitz,15,16 and others.40,93,94 The main
features of these strategies are as follows:
(1) identification of the fastest growing faces of the stable
crystalline modification,
(2) characterization of intermolecular interactions along
the crystallographic direction with fastest growth,
(3) selection of additives that can be incorporated in the
crystalline structure along this direction, and
(4) development of experimental methods to investigate
the effectiveness of the additive to kinetically stabi-
lize the metastable modification.
The selection of additives can be guided by molecular
visualizations of the crystal structure based on geometric
fits13,95 or binding energy calculations.36,96
Growth Mechanisms and Kinetics
Once the nucleation step has been overcome, nuclei grow
into macroscopic crystals. This stage of the crystallization
process is known as crystal growth. The nucleation and
growth processes compete for solute in terms of their
respective dependence on supersaturation, and their rela-
tive rates will determine the crystal size distribution.
Crystal growth is governed by both internal and external
factors. Internal factors such as the three-dimensional
crystal structure and crystal defects will determine the
nature and strength of the intermolecular interactions
between the crystal surface and the solution, whereas
external factors such as temperature, supersaturation,
solvent, and the presence of impurities will affect the type
of interactions at the solid-liquid interface.
Depending on the objectives and applications of growth
rate measurements, the growth rate may be expressed as
(1) overall linear growth rate which is the rate of change
of the volume equivalent diameter with time, (2) linear
growth rate of a face which is the rate of displacement of
a crystal face in a direction perpendicular to the face, and
(3) velocity, height, and spacing of growth steps spreading
across a crystal surface. The linear growth rate of a face
can be expressed in terms of the step velocity, the step
height, and the step spacing. Techniques used for in-situ
measurement of crystal growth rates as a function of
supersaturation include (1) monitoring the crystal popula-
tion by methods that measure particle size and number,97,98
(2) monitoring the growth rates of individual crystal faces
by optical microscopy with the use of a flow cell system
shown in Figure 3,39,95,99-101 and (3) monitoring the devel-
opment of surface morphology at the molecular level by
atomic force microscopy (AFM)101-105 and interferometric
microscopy.37,38
The external shape or morphology of a crystal is a
consequence of the relative growth rates of the faces and
reveals the molecular events occurring at the crystal face-
liquid interfaces during growth. Even when morphology
does not play a significant role in quality control, studying
it is essential to understand the kinetics of crystalliza-
tion.106 The morphological importance of a face (surface
area) is inversely related to its growth rate. Based on these
concepts, one of the standard methods used for identifying
solvents or dissolved additives that influence nucleation
and growth is to investigate the relation between crystal
morphology and growth conditions.13,95,107 A common ap-
proach is to compare the experimentally observed morphol-
ogy with the theoretical morphology and to interpret
differences on the basis of experimental growth parameters
and assumptions of molecular modeling techniques.37-39
Batch-to-batch differences in crystal morphology may
result from small but significant changes in growth condi-
tions during the crystallization process. For instance, the
presence of a small amount of impurity can have a
significant effect on the crystal habit. The most potent
inhibitors of growth are impurities which are structurally
similar to the host molecule (i.e., tailor-made additives and
synthetic impurities). For example, the growth of L-alanine
in the presence of hydrophobic L-amino acids at concentra-
tions as low as 0.02 m (0.3 g additive/100 g solvent or 0.18
g additive/100 g L-alanine) results in a change in crystal
morphology from prismatic to needle-shaped.95,101 The
supersaturation at which crystal growth occurs can also
significantly affect growth rates along different crystal-
lographic axes and crystal habit. Growth of phenytoin
crystals along the a crystallographic axis has a stronger
dependence on supersaturation than growth along the c
axis.39
The process of crystal growth consists of several stages
through which growth units pass. These include (a) trans-
port from the bulk solution to a site at the crystal surface,
(b) adsorption of the growth unit onto the impingement site,
or (c) diffusion from the impingement site to a growth site,
and (d) incorporation into the crystal lattice. Desolvation
can take place in steps b-d; however, the solvent has the
possibility of being adsorbed.
Any one of the above steps may be rate-limiting depend-
ing on the growth conditions, such as the supersaturation,
temperature, additives or solvent, and hydrodynamics of
the system. Consequently, crystal growth mechanisms fall
into two main categories:41-44 volume diffusion control and
surface integration control, and the goals of crystal growth
theories are to determine the source of steps and the rate-
controlling step for crystal growth.
As a crystal grows from a supersaturated solution, the
solute concentration is depleted in the region of the
crystal-solution interface. If diffusion of solute from the
bulk solution to the crystal surface is rate limiting, growth
is volume-diffusion controlled. A diffusion-controlled pro-
cess is not applicable if there is no dependence of growth
rate on hydrodynamic conditions such as flow rate or
stirring rate. In practice it is difficult to completely
eliminate volume diffusion resistance, and experimental
growth kinetics can be misinterpreted as being purely
surface-integration controlled when in fact diffusive resis-
tance is still present. Garside has defined an effectiveness
factor that is a measure of the relative importance of
diffusion and surface integration as the rate-controlling
factors for crystal growth.108
If incorporation into a crystal lattice is the slowest
process, growth is surface-integration controlled. Many
Figure 3sSchematic diagram of a flow system used to measure growth rates
of crystal faces. The volume of the crystallization cell is 300 to 500 µL.
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crystallization studies involving proteins, small organic
electrolytes, and nonelectrolytes have reported growth
controlled by surface integration.37-39,95,99-105 Depending on
the roughness of the crystal surface, layer growth or
continuous growth may result. If the crystal-solution
interface at the molecular level is rough, there are many
potential kink (growth) sites. In this case, continuous or
normal growth models apply. Growth proceeds isotropically
resulting in nonfaceted crystals and responds to very small
gradients in the growth driving chemical potential (tem-
perature, concentration, etc.). If the interface is smooth,
growth proceeds through a layer growth model. Kink sites
are only found on the edges of two-dimensional nuclei or
steps; hence, surface diffusion and surface topography
become more important.
Layer growth models describe the formation of steps by
two mechanisms: screw dislocation and two-dimensional
nucleation. Details of the derivation of these models can
be found in the literature.42,44,109-111
The spiral growth mechanism or screw dislocation model
was first described by Burton, Cabrera, and Frank (BCF).112
Bennema111,113,114 modified this theory for crystals growing
from aqueous solution. Flat crystal surfaces have a high
energy barrier for nucleation at low supersaturations, and
the presence of screw dislocations provides a source of steps
for the addition of growth units in an infinite sequence of
equidistant and parallel steps. In the simplest case, these
steps will develop as a spiral which rotates about its axis
during growth.
Two-dimensional nucleation requires the formation of
clusters above a critical size for growth of layers. The same
concepts discussed in the nucleation section apply to the
nucleation of a two-dimensional cluster above a critical size.
This model accounts for crystal growth at high supersatu-
rations. These models were developed by Volmer115 and
Stranski.116 Variations in the mode that nuclei spread after
being formed lead to the various two-dimensional nucle-
ation models: mononuclear, polynuclear, and birth and
spread.
Each crystal growth model describes the growth rate
dependence on supersaturation, temperature, and face
area. Although the various models can be used to identify
the growth mechanism by fitting the various equations to
the experimentally measured face-growth rate dependence
on supersaturation, it may be difficult to discriminate
between models.39,101,117 This approach is often combined
with observations of surface topography to confirm the
growth mechanism.
Surface microtopographic observations can reveal growth
mechanisms of crystal faces under different growth condi-
tions, as shown for human insulin crystals in Figure 4.
Monitoring the development of surface topography and
transport processes during crystal growth will reveal events
that are not evident from morphology studies. Interactions
of growth units and additives with different crystal planes
exposed on a surface may be deduced from the shape of
two-dimensional nuclei, and the kinetic anisotropy of the
growth steps along crystallographic directions. These tech-
niques have been successfully applied for identifying the
crystal growth mechanisms and kinetics of small mol-
ecules37,38,101 and proteins.102-105,118
Solution-Mediated Transformations
Knowledge of the propensity of a metastable solid phase
to dissolve in a liquid phase from which a stable solid phase
nucleates and grows is crucial in many stages of pharma-
ceutical development, because pharmaceutical solids are
designed to be dissolved and to come in contact with
solvents since the early stages of development (isolated by
crystallization from solution) and during processing (wet
granulation, spray-drying, freeze-drying, etc.). Given that
the sudden disappearance or appearance of a crystalline
modification can threaten process development, character-
ization of the kinetics and mechanisms of solvent-mediated
transformations is of practical importance. It will provide
answers to questions such as the following: What is the
relation between processing conditions and the solid-state
modification manufactured? Is there a correlation between
dissolution conditions, solid phase(s) dissolving, and con-
centration of drug dissolved?
The importance of phase transition kinetics, molecular
interpretations, and process implications are emphasized
by several investigators.5-9,12-14,119 Cardew and Davey5
developed a theoretical framework to investigate solvent-
mediated transformations in terms of dissolution kinetics
of one phase and growth of a second phase. The model
represents the time development of the supersaturation
with respect to the stable phase, or solute concentration
in solution, and solid phase composition during the trans-
formation. The experimental approach involves saturating
the solution with respect to the metastable phase under
consideration and to monitor both solution concentration
and solid phase composition in the presence of the meta-
stable phase, under constant external conditions. More
useful information is obtained from the concentration or
supersaturation profiles than from the solid phase compo-
sition profiles with time. Since the former is related to the
Figure 4sMicrographs of human insulin crystals showing that steps arise by
different mechanisms depending on supersaturation. (a) At low supersaturation,
steps are created by screw dislocations, D. (b) At high supersaturation, c/s
>10, steps occur at the edges of islands as a consequence of two-dimensional
nucleation.
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driving forces that regulate the transformation rate and
can be used to identify the rate-controlling process: dis-
solution or growth. A calculated supersaturation profile
with growth-limited and dissolution-limited regimes is
shown in Figure 5, for the case in which dissolution and
growth are linearly dependent on supersaturation.5,6 Ex-
perimental studies of the phase transitions of organic
crystals have shown this model to be applicable to explain
the solution-mediated transformation kinetics of poly-
morphs5,6,119 and solvates,8 and to be applicable to process
development.119 Some useful experimental techniques for
studying small and large scale crystallization and solution-
mediated transformations are summarized in Table 3.
Summary
In this review we have presented the significance of
crystallization mechanisms and kinetics in directing crys-
tallization pathways. Given the recent advances in com-
putational and analytical techniques that provide access
to the molecular events that direct nucleation and crystal
growth, there is no reason for the development of ill-defined
crystallization processes even when the desired product is
obtained. Understanding the thermodynamic and kinetic
behavior of the system is vital for the design of reliable
processes; thus, at least a holistic approach that identifies
the relevant experimental parameters is required. While
the objectives of formulation or process development may
not explicitly include interpretations at the molecular level,
the information concealed in the interfaces present during
the process, the structure of the solution, and the solids
harvested (crystal structure, morphology, particle size and
number) can be significant in the identification of nucle-
ation and growth mechanisms, and will reveal molecular
events associated with crystallization. Although the sig-
nificance of crystallization mechanisms and kinetics has
been underestimated in the pharmaceutical industry, we
hope that the recent developments in crystallization engi-
neering and techniques will inspire interest in the applica-
tion of this field to pharmaceutical systems.
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